ARS Pharmaceuticals, Inc.

Equities

SPRY

US82835W1080

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-04-24 pm EDT 5-day change 1st Jan Change
8.26 USD -2.82% Intraday chart for ARS Pharmaceuticals, Inc. -8.83% +50.73%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
ARS Pharmaceuticals Insider Sold Shares Worth $928,005, According to a Recent SEC Filing MT
ARS Pharmaceuticals Insider Sold Shares Worth $928,005, According to a Recent SEC Filing MT
Ars Pharmaceuticals Insider Sold Shares Worth $927,735, According to a Recent SEC Filing MT
ARS Pharmaceuticals Files Response to FDA Complete Response Letter For Neffy MT
ARS Pharmaceuticals Submits Response to FDA Letter for Neffy DJ
ARS Pharmaceuticals, Inc. Submits Response to FDA Complete Response Letter for Neffy® (Epinephrine Nasal Spray) CI
ARS Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
ARS Pharmaceuticals, Inc.(NasdaqGM:SPRY) added to S&P Biotechnology Select Industry Index CI
North American Morning Briefing : Stock Futures -2- DJ
Leerink Partners Upgrades ARS Pharmaceuticals to Outperform From Market Perform, Raises Price Target to $18 From $6 MT
ARS Pharmaceuticals Announces neffy Meets Primary Endpoints and Shows Rapid Symptom Control in Phase 2 Urticaria Clinical Study CI
ARS Pharmaceuticals' Repeat Dose Study Shows Epinephrine Nasal Spray as Good as Injection MT
William Blair Upgrades ARS Pharmaceuticals to Outperform From Market Perform MT
ARS Pharmaceuticals, Inc. Announces Favorable Topline Results from Repeat Dosing Study of neffy (Epinephrine Nasal Spray) Under Nasal Allergen Challenge Conditions, Readies Data for Response to FDA?s Complete Response Letter CI
Wedbush Raises ARS Pharmaceuticals' PT to $19 From $13 After Model Adjustments, Keeps Outperform Rating MT
Wedbush Raises ARS Pharmaceuticals' PT to $13 From $5, Says Market Opportunity Intact; Maintains Outperform Rating MT
ARS Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
ARS Pharmaceuticals Says US Food and Drug Administration Schedules Type A Meeting on Allergy Spray for End of October MT
ARS Pharmaceuticals to Meet With FDA on Neffy Rejection DJ
Ars Pharmaceuticals, Inc. Announces Single and Repeat Dose Clinical Study of neffy (epinephrine nasal spray) Published in the Journal of Allergy and Clinical Immunology CI
Ars Pharmaceuticals Insider Bought Shares Worth $319,954, According to a Recent SEC Filing MT
Sector Update: Health Care Stocks Declining Late Thursday Afternoon MT
Sector Update: Health Care MT
ARS Pharmaceuticals Likely to Get Approval for Epinephrine Nasal Spray in H2 2024, Wedbush Says MT
North American Morning Briefing : The Post-Fed -2- DJ
Chart ARS Pharmaceuticals, Inc.
More charts
ARS Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing neffy, for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, administered and nasal spray. Type I allergic reactions are potentially life-threatening hypersensitivity reactions that can occur within minutes of exposure to an allergen and need to be treated immediately to relieve symptoms and prevent further progression.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
8.26 USD
Average target price
19 USD
Spread / Average Target
+130.02%
Consensus
  1. Stock Market
  2. Equities
  3. SPRY Stock
  4. News ARS Pharmaceuticals, Inc.
  5. Silverback Therapeutics : Reports Early Data From Phase 1/1b Study of SBT6050 in Solid Tumors; Stock Slumps